Experimental studies on BC cell lines and laboratory animals have shown the potential of using inhibitors of DNA methyltransferases, histone deacetylases and histone methyltransferases due to the activation of the interferon response by double-stranded transcripts of epigenetically stimulated REs. The gene discussed is PRDM9; the disease is breast cancer.